Babagounj
Strength through joy
There’s been a national shortage of ADHD medication for more than a year and a half. According to the government and industry experts, there are multiple overlapping causes: manufacturing problems, labor issues, supply-chain failures, and a huge rise in demand during the pandemic. But Ascent claims there’s another factor exacerbating the shortage, one that’s completely sui generis: the fact that it’s been shut down by the Drug Enforcement Administration.
“This was a paper discrepancy,” said Jim Walden, Ascent’s attorney. “No one shuts down a company for that.” In May 2023, after more than a year of going back and forth with the DEA, Ascent began laying off workers. In September, Walden filed a lawsuit to compel the government to give a formal response to Ascent’s 2023 quota request. The next day, the DEA served the company with an “order to show cause” — a notice that it intended to revoke its registrations as a drug manufacturer and analytical lab.
The DEA didn’t distinguish between Ascent’s production of ADHD meds, which are stimulants, and its painkillers, which are narcotics. (According to Walden, 80 percent of the company’s controlled-substances revenue comes from stimulants and 20 percent from painkillers.)
“This was a paper discrepancy,” said Jim Walden, Ascent’s attorney. “No one shuts down a company for that.” In May 2023, after more than a year of going back and forth with the DEA, Ascent began laying off workers. In September, Walden filed a lawsuit to compel the government to give a formal response to Ascent’s 2023 quota request. The next day, the DEA served the company with an “order to show cause” — a notice that it intended to revoke its registrations as a drug manufacturer and analytical lab.
The DEA didn’t distinguish between Ascent’s production of ADHD meds, which are stimulants, and its painkillers, which are narcotics. (According to Walden, 80 percent of the company’s controlled-substances revenue comes from stimulants and 20 percent from painkillers.)